Evan A. Stein received his medical degree and PhD, from the University of Witwatersrand Medical School in Johannesburg, South Africa. In 1972 he started the first Lipid Clinic in South Africa, at the Transvaal Memorial Hospital for Children, and described the high gene frequency of Familial Hypercholesterolaemia. He completed his specialist training in Medical Biochemistry at McMaster University Medical Center in Canada prior to moving to the University of Cincinnati, Ohio, where he was on the full-time faculty for 11 years, achieving the rank of Professor of Pathology and Laboratory Medicine as well as Associate Professor of Internal Medicine. In 1988, he moved his clinical and laboratory groups and formed the Metabolic and Atherosclerosis Research Center, specializing in clinical trials affecting lipid metabolism and Medical Research Laboratories a global central lab for clinical trials. In 2002 Medical Research Labs was acquired by Pharmaceutical Product Development Inc. In 2006 he joined Medpace Reference Laboratories as partner and Chief Scientific Officer.
Dr. Stein has had a number of appointments to the National Institutes of Health (NIH) since 1986, including the National Cholesterol Education Program. He served on the Data and Safety Advisory Board of the National Heart, Lung, and Blood Institute Program on Genetics in Hypertension from 1999-2003. In 2006 he was appointed to the FDA Clinical Chemistry and Clinical Toxicology Advisory Panel through 2010.
Dr. Stein sits on the Advisory Board for a number of pharmaceutical and biotech companies and the board of directors of Xenon Pharmaceuticals and Medpace CRO.